Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 2795 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Simultaneous inference of a binary composite endpoint and its components
M. Große Ruse,C. Ritz,L.A. Hothorn
Journal of Biopharmaceutical Statistics.2017;27(1)56
[DOI]
2Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
Fumika Shigiyama,Naoki Kumashiro,Ayako Fuchigami,Takahisa Hirose
Cardiovascular Diabetology.2018;17(1)56
[DOI]
3Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis
Xinhua Xiao,Changjiang Wang,Xiaoyang Lai,Bin Zhang,Liqun Gu,Jianing Hou,Zhiguang Zhou
Journal of Diabetes Investigation.2020;17(1)56
[DOI]
4Proceedings From FDA/A.S.P.E.N. Public Workshop
Daniel H. Teitelbaum,Peggi Guenter,Donna Griebel,Steven A. Abrams,Staffan Bark,Mary Baker,Karyn L. Berry,Bruce R. Bistrian,J. Thomas Brenna,Denis Bonnot,Yvon A. Carpentier,Richard J. Deckelbaum,Mary Hise,Berthold Koletzko,Jay M. Mirtallo,Andrew E. Mulberg,Randall C. O’Reilly,Jonathan Shaffer,Elke von Kleist,Gary P. Zaloga,Thomas R. Ziegler
Journal of Parenteral and Enteral Nutrition.2015;39(7)768
[DOI]
5Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
Ayako Fuchigami,Fumika Shigiyama,Toru Kitazawa,Yosuke Okada,Takamasa Ichijo,Mariko Higa,Toru Hiyoshi,Ikuo Inoue,Kaoru Iso,Hidenori Yoshii,Takahisa Hirose,Naoki Kumashiro
Cardiovascular Diabetology.2020;19(1)768
[DOI]
6A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes
Stuart A. Ross
Current Medical Research and Opinion.2015;31(1)125
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal